Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
– Topline data remains on track for second quarter of 2024 –
MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease. AJ201 is currently the lead drug candidate in the clinic for SBMA, and topline data are anticipated in the second quarter of 2024.
Related news for (ATXI)
- Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Sidoti Events, LLC’s Virtual January Micro-Cap Conference
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
- Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
- Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol